Connection

SUSAN HILSENBECK to Mice

This is a "connection" page, showing publications SUSAN HILSENBECK has written about Mice.
Connection Strength

0.753
  1. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.018
  2. Reproducibility, sources of variability, pooling, and sample size: important considerations for the design of high-density oligonucleotide array experiments. J Gerontol A Biol Sci Med Sci. 2004 Apr; 59(4):306-15.
    View in: PubMed
    Score: 0.018
  3. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J Clin Invest. 2023 12 15; 133(24).
    View in: PubMed
    Score: 0.017
  4. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022 11; 41(48):5214-5222.
    View in: PubMed
    Score: 0.016
  5. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2021 12; 1(3):178-193.
    View in: PubMed
    Score: 0.015
  6. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. J Pathol. 2022 02; 256(2):186-201.
    View in: PubMed
    Score: 0.015
  7. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022 01; 15(1):3-10.
    View in: PubMed
    Score: 0.015
  8. A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis. Cancer Res. 2021 09 01; 81(17):4441-4454.
    View in: PubMed
    Score: 0.014
  9. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.
    View in: PubMed
    Score: 0.014
  10. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
    View in: PubMed
    Score: 0.014
  11. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
    View in: PubMed
    Score: 0.012
  12. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
    View in: PubMed
    Score: 0.012
  13. Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. Cancer Res. 2019 01 01; 79(1):61-71.
    View in: PubMed
    Score: 0.012
  14. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42.
    View in: PubMed
    Score: 0.012
  15. NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res. 2017 07 15; 77(14):3802-3813.
    View in: PubMed
    Score: 0.011
  16. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
    View in: PubMed
    Score: 0.011
  17. Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater. 2017 08; 58:466-478.
    View in: PubMed
    Score: 0.011
  18. CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat Commun. 2016 11 21; 7:13362.
    View in: PubMed
    Score: 0.011
  19. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
    View in: PubMed
    Score: 0.010
  20. Research Resource: Roles for Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) in Systems Metabolism. Mol Endocrinol. 2016 May; 30(5):557-72.
    View in: PubMed
    Score: 0.010
  21. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
    View in: PubMed
    Score: 0.010
  22. Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res. 2015 Nov 18; 17:141.
    View in: PubMed
    Score: 0.010
  23. An essential role for Ga(i2) in Smoothened-stimulated epithelial cell proliferation in the mammary gland. Sci Signal. 2015 Sep 15; 8(394):ra92.
    View in: PubMed
    Score: 0.010
  24. Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep. 2015 Jul 21; 12(3):511-24.
    View in: PubMed
    Score: 0.010
  25. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
    View in: PubMed
    Score: 0.009
  26. Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice. FASEB J. 2015 Aug; 29(8):3537-48.
    View in: PubMed
    Score: 0.009
  27. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
    View in: PubMed
    Score: 0.009
  28. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015 May; 5(5):520-33.
    View in: PubMed
    Score: 0.009
  29. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
    View in: PubMed
    Score: 0.009
  30. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
    View in: PubMed
    Score: 0.009
  31. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.
    View in: PubMed
    Score: 0.009
  32. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
    View in: PubMed
    Score: 0.009
  33. Agonistic induction of PPAR? reverses cigarette smoke-induced emphysema. J Clin Invest. 2014 Mar; 124(3):1371-81.
    View in: PubMed
    Score: 0.009
  34. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1008-13.
    View in: PubMed
    Score: 0.009
  35. Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.
    View in: PubMed
    Score: 0.009
  36. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife. 2013 Dec 31; 2:e00996.
    View in: PubMed
    Score: 0.009
  37. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.
    View in: PubMed
    Score: 0.008
  38. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013 Jun 01; 73(11):3470-80.
    View in: PubMed
    Score: 0.008
  39. Research resource: tissue- and pathway-specific metabolomic profiles of the steroid receptor coactivator (SRC) family. Mol Endocrinol. 2013 Feb; 27(2):366-80.
    View in: PubMed
    Score: 0.008
  40. Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. Stem Cells. 2013 Jan; 31(1):178-89.
    View in: PubMed
    Score: 0.008
  41. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
    View in: PubMed
    Score: 0.008
  42. Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. Cell Metab. 2012 May 02; 15(5):752-63.
    View in: PubMed
    Score: 0.008
  43. Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci Transl Med. 2012 Jan 18; 4(117):117ra9.
    View in: PubMed
    Score: 0.008
  44. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
    View in: PubMed
    Score: 0.007
  45. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121.
    View in: PubMed
    Score: 0.007
  46. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. BMC Cancer. 2011 Aug 25; 11:377.
    View in: PubMed
    Score: 0.007
  47. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2778-83.
    View in: PubMed
    Score: 0.007
  48. Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011 Oct 27; 30(43):4399-409.
    View in: PubMed
    Score: 0.007
  49. Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
    View in: PubMed
    Score: 0.007
  50. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
    View in: PubMed
    Score: 0.007
  51. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61.
    View in: PubMed
    Score: 0.007
  52. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med. 2010 Oct 27; 2(55):55ra79.
    View in: PubMed
    Score: 0.007
  53. P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis. Breast Cancer Res. 2010; 12(5):R73.
    View in: PubMed
    Score: 0.007
  54. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia. 2010 Sep; 12(9):718-26.
    View in: PubMed
    Score: 0.007
  55. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 2010 Jun 15; 70(12):4868-79.
    View in: PubMed
    Score: 0.007
  56. In vitro and in vivo magnetic resonance imaging (MRI) detection of GFP through magnetization transfer contrast (MTC). Neuroimage. 2010 Apr 01; 50(2):375-82.
    View in: PubMed
    Score: 0.007
  57. Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Res. 2009; 11(4):R61.
    View in: PubMed
    Score: 0.006
  58. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
    View in: PubMed
    Score: 0.006
  59. Prevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3. Clin Transl Sci. 2009 Feb; 2(1):41-9.
    View in: PubMed
    Score: 0.006
  60. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74.
    View in: PubMed
    Score: 0.006
  61. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.
    View in: PubMed
    Score: 0.006
  62. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.
    View in: PubMed
    Score: 0.006
  63. Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells. 2008 Dec; 26(12):3205-9.
    View in: PubMed
    Score: 0.006
  64. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008 Jun 15; 68(12):4674-82.
    View in: PubMed
    Score: 0.006
  65. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 2008 Jun; 1(1):45-55.
    View in: PubMed
    Score: 0.006
  66. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31.
    View in: PubMed
    Score: 0.006
  67. Conditional overexpression of Stat3alpha in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern. J Leukoc Biol. 2007 Oct; 82(4):975-85.
    View in: PubMed
    Score: 0.006
  68. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development. 2007 Mar; 134(6):1231-42.
    View in: PubMed
    Score: 0.005
  69. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18.
    View in: PubMed
    Score: 0.005
  70. Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat. 2006 Dec; 5(6):565-71.
    View in: PubMed
    Score: 0.005
  71. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
    View in: PubMed
    Score: 0.005
  72. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9.
    View in: PubMed
    Score: 0.005
  73. The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol. 2006 Jul 15; 295(2):589-603.
    View in: PubMed
    Score: 0.005
  74. Transcriptional profiling of mammary gland side population cells. Stem Cells. 2006 Apr; 24(4):1065-74.
    View in: PubMed
    Score: 0.005
  75. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology. 2005 Aug; 146(8):3490-505.
    View in: PubMed
    Score: 0.005
  76. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 2005 Apr 15; 65(8):3462-9.
    View in: PubMed
    Score: 0.005
  77. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 2004 May 15; 64(10):3525-32.
    View in: PubMed
    Score: 0.004
  78. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.004
  79. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
    View in: PubMed
    Score: 0.004
  80. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002 Nov 15; 62(22):6376-80.
    View in: PubMed
    Score: 0.004
  81. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
    View in: PubMed
    Score: 0.004
  82. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.
    View in: PubMed
    Score: 0.004
  83. Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci. 2001 Dec; 952:23-35.
    View in: PubMed
    Score: 0.004
  84. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
    View in: PubMed
    Score: 0.003
  85. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer. 2000 Dec; 36(18):2430-6.
    View in: PubMed
    Score: 0.003
  86. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000 Sep; 6(9):3696-704.
    View in: PubMed
    Score: 0.003
  87. MGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):306-14.
    View in: PubMed
    Score: 0.003
  88. cDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction. Mech Ageing Dev. 2000 Jun 20; 115(3):157-74.
    View in: PubMed
    Score: 0.003
  89. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
    View in: PubMed
    Score: 0.003
  90. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res. 1999 Mar 01; 59(5):1049-53.
    View in: PubMed
    Score: 0.003
  91. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol. 1999; 43(5):402-8.
    View in: PubMed
    Score: 0.003
  92. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5.
    View in: PubMed
    Score: 0.003
  93. Apoptosis in the murine rd1 retinal degeneration is predominantly p53-independent. Mol Vis. 1998 Mar 02; 4:5.
    View in: PubMed
    Score: 0.003
  94. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.
    View in: PubMed
    Score: 0.003
  95. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13.
    View in: PubMed
    Score: 0.003
  96. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Cancer Res. 1997 Feb 15; 57(4):600-3.
    View in: PubMed
    Score: 0.003
  97. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol. 1997 Feb; 17(2):723-31.
    View in: PubMed
    Score: 0.003
  98. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997; 17(3):113-23.
    View in: PubMed
    Score: 0.003
  99. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.
    View in: PubMed
    Score: 0.002
  100. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994; 34(2):89-95.
    View in: PubMed
    Score: 0.002
  101. Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2. J Surg Res. 1988 Dec; 45(6):523-30.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.